Antibody Drug Conjugate market Growth Analysis and Forecast by 2035
Driven by the success of 14 approved antibody drug conjugates (ADCs) and a promising development pipeline, the field of antibody drug conjugates has gained significant traction in the last few years
Roots Analysis is pleased to announce the publication of its recent study, titled,“ Antibody Drug Conjugate Market (7th Edition) Market, 2023-2035.”
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geography. Amongst other elements, the report includes:
§ A detailed assessment of the market landscape of close to 400 antibody drug conjugates / ADC therapeutics that are either approved or being evaluated in different stages of development
§ An insightful competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.
§ Elaborate profiles of leading antibody drug conjugate companies (shortlisted based on sales revenue of 2022) and their respective product portfolios.
§ An in-depth analysis of completed, ongoing, and planned clinical studies of various antibody drug conjugates
§ An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibody drug conjugates
§ An assessment of various therapeutics that are being evaluated in combination with antibody-drug conjugates.
§ A detailed analysis of partnerships established by stakeholders engaged in this industry, since 2014
§ An analysis of the various funding and investments made in the ADC domain, in the recent past
§ An in-depth analysis of the various patents that have been filed / granted related to antibody drug conjugates
§ A study of the various grants that have been awarded to research institutes engaged in conducting research related to antibody drug conjugates, since 2016
§ An elaborate discussion on commercialization strategies adopted by various drug developers for their respective products
§ An analysis of the key promotional strategies that have been adopted by the developers of marketed products
§ An insightful success protocol analysis of recently approved ADC therapeutics, based on several relevant parameters
§ An overview on of various conjugation and linker technologies along with their types that are presently being employed in the designing and development of antibody drug conjugates
§ An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in antibody drug conjugates
§ An elaborate discussion on various factors that form the basis for the pricing of antibody drug conjugate products
§ A case study on manufacturing of antibody drug conjugates, highlighting the key challenges, and a list of contract service providers that are involved in the ADC market.
§ A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving antibody-drug conjugates
§ A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Target Disease Indication
§ Acute Lymphoblastic Leukemia
§ Breast Cancer
§ B-Cell Lymphoma
§ Cervical Cancer
§ Gastric Cancer
§ Lung Cancer
§ Multiple Myeloma
§ Renal Cancer
§ Other Target Disease Indications
§ Therapeutic Area
§ Hematological Cancer
§ Solid Tumor
§ Linker
§ Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)
§ Maleimide
§ Maleimidocaproyl
§ Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate
§ Tetrapeptide-Based Linker
§ Valine-Alanine
§ Valine-Citrulline
§ Other Linkers
§ Payload
§ DM1
§ DM4
§ Duocarmycin
§ Monomethyl auristatin E (MMAE)
§ Monomethyl auristatin F (MMAF)
§ Ozogamicin
§ SG3199
§ SN-38 / Irinotecan
§ Other Payloads
§ Target Antigen
§ BCMA (TNFRSF17 / BCM)
§ CD19
§ CD22
§ CD30
§ CD79b
§ CEACAM5
§ HER-2 (ERBB2)
§ Nectin 4
§ Tissue factor
§ TROP-2
§ Other Target Antigen
§ Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific and Rest of the World
Key companies covered in the report
§ ADC Therapeutics
§ Astellas Pharma
§ AstraZeneca
§ Byondis
§ Daiichi Sankyo
§ Genentech
§ Gilead Sciences
§ ImmunoGen
§ Pfizer
§ RemeGen
To view more details on this report, click on the link:
https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market/270.html
News article
Learn from experts: do you know about these emerging industry trends?
Investment Opportunities in Women’s Digital Health
Genotoxicity Testing: Unlocking the Future Safety Assessment Opportunities
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
contact:
Ben Johnson
+1 (415) 800 3415
English